Combination therapies: CMA prioritization statement

17 November 2023
cma-large

The UK’s Competition and Markets Authority (CMA) has clarified the circumstances under which it will not prioritize enforcement action against pharmaceutical companies when they implement a specific ‘negotiation framework’ to make more combination therapies available on the National Health Service (NHS).

The CMA’s statement applies only where certain market features are present and particular conditions are met.

The statement is an international first from any competition authority taking action to support NHS patient access to clinically important combination therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical